143 related articles for article (PubMed ID: 18617603)
1. Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat.
Albayati ZA; Dwoskin LP; Crooks PA
Drug Metab Dispos; 2008 Oct; 36(10):2024-9. PubMed ID: 18617603
[TBL] [Abstract][Full Text] [Related]
2. N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity.
Dwoskin LP; Wooters TE; Sumithran SP; Siripurapu KB; Joyce BM; Lockman PR; Manda VK; Ayers JT; Zhang Z; Deaciuc AG; McIntosh JM; Crooks PA; Bardo MT
J Pharmacol Exp Ther; 2008 Aug; 326(2):563-76. PubMed ID: 18460644
[TBL] [Abstract][Full Text] [Related]
3. Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo.
Rahman S; Zhang Z; Papke RL; Crooks PA; Dwoskin LP; Bardo MT
Br J Pharmacol; 2008 Feb; 153(4):792-804. PubMed ID: 18059317
[TBL] [Abstract][Full Text] [Related]
4. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices.
Smith AM; Dhawan GK; Zhang Z; Siripurapu KB; Crooks PA; Dwoskin LP
Biochem Pharmacol; 2009 Oct; 78(7):889-97. PubMed ID: 19631612
[TBL] [Abstract][Full Text] [Related]
5. Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats.
Neugebauer NM; Zhang Z; Crooks PA; Dwoskin LP; Bardo MT
Psychopharmacology (Berl); 2006 Mar; 184(3-4):426-34. PubMed ID: 16220336
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).
Dwoskin LP; Joyce BM; Zheng G; Neugebauer NM; Manda VK; Lockman P; Papke RL; Bardo MT; Crooks PA
Biochem Pharmacol; 2007 Oct; 74(8):1271-82. PubMed ID: 17727820
[TBL] [Abstract][Full Text] [Related]
7. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens.
Rahman S; Neugebauer NM; Zhang Z; Crooks PA; Dwoskin LP; Bardo MT
Neuropharmacology; 2007 Mar; 52(3):755-63. PubMed ID: 17097117
[TBL] [Abstract][Full Text] [Related]
8. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier.
Lockman PR; Manda VK; Geldenhuys WJ; Mittapalli RK; Thomas F; Albayati ZF; Crooks PA; Dwoskin LP; Allen DD
J Pharmacol Exp Ther; 2008 Jan; 324(1):244-50. PubMed ID: 17921191
[TBL] [Abstract][Full Text] [Related]
9. The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.
Rahman S; Neugebauer NM; Zhang Z; Crooks PA; Dwoskin LP; Bardo MT
Eur J Pharmacol; 2008 Dec; 601(1-3):103-5. PubMed ID: 19000671
[TBL] [Abstract][Full Text] [Related]
10. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.
Smith AM; Pivavarchyk M; Wooters TE; Zhang Z; Zheng G; McIntosh JM; Crooks PA; Bardo MT; Dwoskin LP
Biochem Pharmacol; 2010 Aug; 80(3):402-9. PubMed ID: 20346923
[TBL] [Abstract][Full Text] [Related]
11. bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
Wooters TE; Smith AM; Pivavarchyk M; Siripurapu KB; McIntosh JM; Zhang Z; Crooks PA; Bardo MT; Dwoskin LP
Br J Pharmacol; 2011 May; 163(2):346-57. PubMed ID: 21232049
[TBL] [Abstract][Full Text] [Related]
12. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.
Dwoskin LP; Sumithran SP; Zhu J; Deaciuc AG; Ayers JT; Crooks PA
Bioorg Med Chem Lett; 2004 Apr; 14(8):1863-7. PubMed ID: 15050617
[TBL] [Abstract][Full Text] [Related]
13. Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation.
Zheng G; Zhang Z; Pivavarchyk M; Deaciuc AG; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2007 Dec; 17(24):6734-8. PubMed ID: 18029180
[TBL] [Abstract][Full Text] [Related]
14. r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.
Beckmann JS; Meyer AC; Pivavarchyk M; Horton DB; Zheng G; Smith AM; Wooters TE; McIntosh JM; Crooks PA; Bardo MT; Dwoskin LP
Neurochem Res; 2015 Oct; 40(10):2121-30. PubMed ID: 26227997
[TBL] [Abstract][Full Text] [Related]
15. bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors.
Ayers JT; Dwoskin LP; Deaciuc AG; Grinevich VP; Zhu J; Crooks PA
Bioorg Med Chem Lett; 2002 Nov; 12(21):3067-71. PubMed ID: 12372503
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
[TBL] [Abstract][Full Text] [Related]
17. [UPLC-MS/MS determination of tanshinone ⅡA, salvianolic acid B and ginsenoside Rg₁ in Fufang Danshen preparation in rat plasma and brain tissues].
Zhang J; Liu SL; Wang H; Yang GP; Li JP; Liu SK; Tang Z; Pei Q; Huang PH
Zhongguo Zhong Yao Za Zhi; 2017 Feb; 42(3):580-586. PubMed ID: 28952268
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
19. A sensitive technique for the detection of the alpha 7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain.
Turek JW; Kang CH; Campbell JE; Arneric SP; Sullivan JP
J Neurosci Methods; 1995; 61(1-2):113-8. PubMed ID: 8618408
[TBL] [Abstract][Full Text] [Related]
20. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
